ImmunoMet

본문 바로가기


Overview

Leveraging unique metabolic signatures of cancer and immune cells to enhance anti-cancer therapy

As a leader in the field of cancer metabolism and immunometabolism, ImmunoMet Therapeutics continues to strive to be the forerunner in bringing the best possible innovative therapies to cancer patients.


ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. With our devotion to research and development, we aim to bring multiple metabolic regulators that can be combined with and enhance the current standard-of-care or new therapies to control cancer recurrence.


Copyright © ImmunoMet. All rights reserved.